(Information sent by the signatory company)

- ScreenPoint Medical Introduces Transpara® Breast AI, Designed to Improve Cancer Detection and Support Single-Reader Detection in ECR

AI-supported screening delivering real-world clinical results in research studies presented in ECR

VIENNA, Feb. 21, 2024 /PRNewswire/ -- ScreenPoint Medical will present its industry-leading Transpara Breast AI at the 2024 European Congress of Radiology (ECR) meeting, February 28 to March 3 2024 (booth no. AI-31 in Expo Hall X1). Transpara provides radiologists with a “second pair” of eyes to help detect cancers earlier and reduce recovery rates.

Transpara continues to deliver proven clinical and workflow benefits in mammography screening in global practice and clinical research. These benefits are the subject of 4 presentations and 3 posters that will be presented at ECR 2024:

In the first randomized controlled trial of its kind, researchers analyzed cancer detection rates and types of cancers detected in the entire MASAI study population. AI-supported detection resulted in significant and substantial improvements compared to non-AI double reading. These results can be seen in: "Cancer Detection in Relation to Type and Stage in the Mammography Screening with Artificial Intelligence (MASAI) Randomized Trial" (RPS-2002, ACV Research Stage 2, March 2, 2002). p.m.).

In another prospective clinical trial, researchers evaluated AI to safely reduce workload by excluding low-risk cases for human reading and applying double reading to the rest. This presentation that can be viewed is: "Is it worth reading low-risk breast cancer screening mammograms determined by an artificial intelligence (AI) system? A prospective population-based study for DM and DBT (AITIC trial)" (RPS -1202, Stroke Investigation Stage 1, March 1, 8 a.m.). The results demonstrated that AI-based classification, which excludes low-risk mammograms from human reading, leads to a substantial reduction in reading workload in breast cancer detection without negatively affecting performance.

Additional presentations include:

The e-posters include:

"We are pleased that users and researchers continue to see the value of Transpara in improving the mammography screening process. It is important to note that these studies reflect overall consistency in the performance of Transpara. In fact, we now have retrospective controlled trials, Prospective, randomized trials showing "Transpara provides radiologists with the ability to effectively detect cancer in its early stages while keeping recovery rates constant. "Women should not have to make compromises," said Mark Koeniguer, CEO of ScreenPoint Medical.

Transpara has FDA approval and European regulatory approval (CE mark) for both anomaly detection and density assessment for use with 2D and 3D mammograms from multiple manufacturers. Used by hundreds of leading centers in more than 30 countries, Transpara is designed to work simultaneously with radiologists. Research shows that up to 45% of interval cancers can be detected earlier using Transpara, while helping to improve reading workflow.

About ScreenPoint Medical

ScreenPoint Medical translates cutting-edge machine learning research into technology accessible to radiologists to improve screening workflow, decision confidence, and breast cancer risk assessment. Transpara is trusted by radiologists around the world because it has been developed by experts in machine learning and image analysis and updated with feedback from users of world-renowned breast imagers. See all tests at: screenpoint-medical.com

Photo - https://mma.prnewswire.com/media/2344059...Logo - https://mma.prnewswire.com/media/1582198...

View original content: https://www.prnewswire.com/news-releases/screenpoint-medical-presenta-la-ia-mamaria-transpara-disenada-para-mejorar-la-deteccion-del-cancer-302067412.html